Trending Stock News

Neurocrine Biosciences (NBIX) Holder Raymond James & Associates Lowered Holding by $1.04 Million as Stock Rose; Apple Computer (AAPL) Share Value Declined While Beach Investment Management Has Raised Stake

Apple Inc. (NASDAQ:AAPL) Logo

Beach Investment Management Llc increased its stake in Apple Computer (AAPL) by 30.21% based on its latest 2017Q4 regulatory filing with the SEC. Beach Investment Management Llc bought 2,480 shares as the company’s stock declined 3.81% with the market. The institutional investor held 10,690 shares of the computer manufacturing company at the end of 2017Q4, valued at $1.81M, up from 8,210 at the end of the previous reported quarter. Beach Investment Management Llc who had been investing in Apple Computer for a number of months, seems to be bullish on the $926.90B market cap company. The stock increased 0.23% or $0.43 during the last trading session, reaching $188.58. About 15.45 million shares traded. Apple Inc. (NASDAQ:AAPL) has risen 19.49% since May 25, 2017 and is uptrending. It has outperformed by 7.94% the S&P500.

Raymond James & Associates decreased its stake in Neurocrine Biosciences Inc (NBIX) by 59.75% based on its latest 2017Q4 regulatory filing with the SEC. Raymond James & Associates sold 13,550 shares as the company’s stock rose 13.16% while stock markets declined. The institutional investor held 9,126 shares of the health care company at the end of 2017Q4, valued at $708,000, down from 22,676 at the end of the previous reported quarter. Raymond James & Associates who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be less bullish one the $8.47B market cap company. The stock decreased 0.46% or $0.44 during the last trading session, reaching $94.2. About 331,257 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since May 25, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.

More important recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Streetinsider.com which released: “Baird KOL Panel Says Neurocrine Biosciences’ (NBIX) Opportunity Could Be Double Expectations” on May 16, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More”, Streetinsider.com published: “UPDATE: Neurocrine Bio. (NBIX) PT Raised to $120 at Oppenheimer” on May 14, 2018. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Fred’s, Nexstar Broadcasting Group, CNO Financial …” with publication date: May 14, 2018.

Since January 2, 2018, it had 0 buys, and 24 insider sales for $40.25 million activity. 105,983 shares were sold by GORMAN KEVIN CHARLES, worth $8.50 million on Monday, February 5. Lippoldt Darin had sold 2,737 shares worth $227,494 on Monday, February 5. Shares for $169,914 were sold by Gano Kyle. On Wednesday, January 24 RASTETTER WILLIAM H sold $855,000 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 9,500 shares. $138,499 worth of stock was sold by OBrien Christopher Flint on Tuesday, January 16. LYONS GARY A also sold $423,341 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Thursday, February 15.

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 58 analyst reports since August 18, 2015 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, July 11 report. The rating was initiated by Deutsche Bank with “Buy” on Thursday, November 3. The rating was maintained by Leerink Swann on Thursday, November 2 with “Outperform”. The firm earned “Buy” rating on Monday, January 8 by Piper Jaffray. The firm earned “Buy” rating on Friday, August 4 by Oppenheimer. The company was maintained on Monday, June 26 by Jefferies. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Friday, October 20 by BMO Capital Markets. BMO Capital Markets maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Wednesday, November 1. BMO Capital Markets has “Buy” rating and $109.0 target. The firm has “Buy” rating given on Monday, September 25 by Cowen & Co. The firm has “Buy” rating given on Thursday, September 7 by Oppenheimer.

Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.35, from 1.66 in 2017Q3. It dropped, as 18 investors sold NBIX shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported. Rock Springs LP owns 486,000 shares for 1.71% of their portfolio. Art Advisors Ltd Com holds 0.32% or 92,700 shares in its portfolio. Barclays Public Limited Liability Corporation has 33,139 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 5,904 shares. Bancorp Of Montreal Can has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Comerica Bankshares stated it has 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). State Board Of Administration Of Florida Retirement Sys stated it has 116,057 shares or 0.02% of all its holdings. Schroder Investment Management Group, a Maine-based fund reported 28,976 shares. Trexquant Limited Partnership owns 3,005 shares. Jefferies Gp Ltd Liability Com, New York-based fund reported 6,868 shares. Proshare Ltd Com reported 50,064 shares. Cibc Asset Management Inc holds 0% or 2,966 shares. Davidson Kempner LP owns 80,200 shares. Nordea Invest Mngmt Ab has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). 1,918 were reported by Crow Point Partners Ltd Liability Com.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on August, 2. They expect $-0.17 EPS, up 75.00% or $0.51 from last year’s $-0.68 per share. After $-0.47 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -63.83% EPS growth.

Raymond James & Associates, which manages about $75.99 billion and $54.42B US Long portfolio, upped its stake in Apple Inc (NASDAQ:AAPL) by 4.88M shares to 4.96M shares, valued at $838.76M in 2017Q4, according to the filing. It also increased its holding in Paychex Inc (NASDAQ:PAYX) by 331,560 shares in the quarter, for a total of 379,260 shares, and has risen its stake in Devon Energy Corp New (NYSE:DVN).

Since December 7, 2017, it had 0 insider purchases, and 10 sales for $47.05 million activity. On Wednesday, April 4 the insider Riccio Daniel J. sold $2.94M. Another trade for 4,867 shares valued at $910,129 was made by KONDO CHRIS on Wednesday, May 16. 15,653 shares valued at $2.90 million were sold by WILLIAMS JEFFREY E on Tuesday, May 8. $6.75 million worth of Apple Inc. (NASDAQ:AAPL) shares were sold by AHRENDTS ANGELA J. The insider SCHILLER PHILIP W sold 69,491 shares worth $11.56M. $6.51 million worth of Apple Inc. (NASDAQ:AAPL) was sold by LEVINSON ARTHUR D.

Among 56 analysts covering Apple Inc. (NASDAQ:AAPL), 37 have Buy rating, 1 Sell and 18 Hold. Therefore 66% are positive. Apple Inc. had 417 analyst reports since July 21, 2015 according to SRatingsIntel. Drexel Hamilton maintained Apple Inc. (NASDAQ:AAPL) rating on Wednesday, July 27. Drexel Hamilton has “Buy” rating and $115 target. Oppenheimer downgraded the shares of AAPL in report on Wednesday, April 27 to “Perform” rating. The firm earned “Neutral” rating on Friday, September 11 by Mizuho. Oppenheimer maintained the stock with “Outperform” rating in Friday, September 11 report. The rating was downgraded by Stifel Nicolaus on Wednesday, March 7 to “Hold”. The firm earned “Buy” rating on Monday, March 5 by Robert W. Baird. The stock of Apple Inc. (NASDAQ:AAPL) has “Buy” rating given on Wednesday, September 13 by BMO Capital Markets. The company was maintained on Wednesday, October 28 by Susquehanna. The stock of Apple Inc. (NASDAQ:AAPL) earned “Overweight” rating by Piper Jaffray on Wednesday, October 28. On Monday, February 12 the stock rating was maintained by Wells Fargo with “Hold”.

Investors sentiment increased to 0.73 in 2017 Q4. Its up 0.03, from 0.7 in 2017Q3. It is positive, as 50 investors sold AAPL shares while 1023 reduced holdings. 151 funds opened positions while 637 raised stakes. 2.98 billion shares or 0.18% more from 2.97 billion shares in 2017Q3 were reported. Artisan Partnership holds 480,511 shares. Madison Holding holds 191,143 shares or 0.55% of its portfolio. Commerce Of Vermont holds 2.52% in Apple Inc. (NASDAQ:AAPL) or 160,251 shares. Stonebridge Ltd Limited Liability Company invested in 4.75% or 122,740 shares. Moreover, Optimum Inv Advsrs has 3.58% invested in Apple Inc. (NASDAQ:AAPL) for 66,557 shares. 1St Source National Bank owns 71,712 shares. Moreover, Valmark Advisers has 0.07% invested in Apple Inc. (NASDAQ:AAPL). Janney Capital Llc has invested 0.99% in Apple Inc. (NASDAQ:AAPL). Telemus Cap Limited Liability Com stated it has 140,935 shares. Todd Asset Mgmt Limited invested in 255,843 shares or 1.17% of the stock. Peavine Lc holds 1,318 shares. Magellan Asset Mngmt, Australia-based fund reported 16.71M shares. Headinvest Ltd Llc holds 0.83% or 15,878 shares in its portfolio. Carlson Capital Management invested 0.41% of its portfolio in Apple Inc. (NASDAQ:AAPL). Community Financial Services Lc owns 32,798 shares.

More notable recent Apple Inc. (NASDAQ:AAPL) news were published by: Livetradingnews.com which released: “Apple Inc. (NASDAQ:AAPL) Stock Consolidating” on May 25, 2018, also Seekingalpha.com with their article: “Apple Ignores Tesla, Instead Partners With Volkswagen” published on May 24, 2018, Thestreet.com published: “How to Trade Apple Ahead of Alphabet’s Launch of YouTube Music” on May 21, 2018. More interesting news about Apple Inc. (NASDAQ:AAPL) were released by: Bizjournals.com and their article: “Apple’s ties to Triangle run through Raleigh, Durham” published on May 25, 2018 as well as Seekingalpha.com‘s news article titled: “Apple: Still A Bargain” with publication date: May 23, 2018.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *